Osteo-Pharma announces Scientific Advisory Board

Osteo-Pharma, a Dutch Life Sciences company developing novel pharmaceuticals and medical devices to improve the local healing of bone fractures and defects, announced its Scientific Advisory Board (SAB) comprising experts in the field of bone and dental regenerative biology from the U.S. and Europe.

read more

Osteo-Pharma receives up to € 2 Million Innovation Credit from Dutch Government

Oss, The Netherlands – June 16, 2016 – Osteo-Pharma BV, a Life Sciences company focusing on the development of local treatments to improve the healing of bone fractures and defects, announces today that it has received an innovation credit of up to € 2 million from the Rijksdienst voor Ondernemers (RVO), an agency executing programs for the Dutch Ministry of Economic Affairs, Agriculture and Innovation.

read more
About Osteo-Pharma Osteo-Pharma is a Life Sciences company focused on the development of local treatments to improve the healing of bone fracture and defects. It’s proprietary OsteoActivator platform is used to develop biodegradable films, microspheres and coatings for implants with sustained release of small molecule drugs that enhance bone formation while simultaneously inhibiting bone resorption. The company is currently in mid-late stage pre-clinical development with various projects and anticipates to initiate the first human clinical trials in the course of 2017/2018.